The Mirpuri Foundation announces groundbreaking research as a shareholder and investor of TTxD – Trained Therapeutix Discovery, Inc. (“TTxD”), the biotech company founded by Jean Boulle Medtech at the forefront of a unique immunotherapy strategy, that is now testing its platform for a completely new approach for treating Acute Respiratory Distress Syndrome (“ARDS”), which could prove to be highly effective in saving the lives of Covid–19 patients.

TTxD’s proprietary technology is based on over a decade of research and development using bioengineering methods to produce nanobiologic therapeutics that can induce an immune response against tumors or dampen hyperinflammation after organ transplantation. TTxD has an established library of nanobiologic therapeutics relevant to many applications and potentially fatal diseases, including ARDS. 

Under an exclusive license from the Icahn School of Medicine at Mount Sinai in New York and Radboud University Medical Center in the Netherlands, TTxD applies advanced bioengineering methods to develop nanobiologic therapeutics. Nanobiologics are materials constructed from molecular building blocks that our body produces naturally. The advantage of this approach is that nanobiologic therapy ‘hijacks’ natural mechanisms to regulate the immune system with materials that are inherently well tolerated by the body. 

Leighton Durham, Director of Jean Boulle Medtech, said: “Our exceptional team has a unique vision and the backing of many in the global scientific community for their ground-breaking work. There is a real chance to save lives through the further development of these technologies for Covid-19 patients.”

Paulo Mirpuri, President of the Mirpuri Foundation, states that: “Medical Research has always been one of the key pillars of the Mirpuri Foundation. In such unprecedented times like the ones we are living now, it is with a great sense of responsibility and commitment that we announce that this project took a vital turn to help save Covid-19 patients. Moreover, the research is addressing the pandemic now but it will have a beneficial health impact long after the crisis.”


The Mirpuri Foundation is a non-profit organization based in Portugal, and founded by entrepreneur Paulo Mirpuri with the aim of contributing to a better world for future generations.

With its belief that leading by example is the best way to change mindsets, the Mirpuri Foundation fosters cooperation between legislators, corporations, communities and individuals.

The Mirpuri Foundation acts in six distinct areas: Marine Conservation, Wildlife Conservation, the Performing Arts, Social Responsibility, Medical Research, and Aviation. The foundation’s commitment to sustainability is transversal and is reflected in all its activities.

The Mirpuri Foundation is synonymous with technology, research, information and innovation. Allied to these characteristics are the values of integrity, perseverance and altruism in order to better impact the planet.


Jean Boulle Medtech is involved in exploring and developing new technologies in a range of life saving areas of medicine:


Jean Boulle Medtech founded Tendyne Holdings, Inc., which developed the most important transcatheter mitral valve implant (“TMVI”) device in existence worldwide. Tendyne’s global success underlines Jean Boulle Medtech’s strategy as well as its valuable technical and commercial expertise. In September 2015 the Jean Boulle Group announced that an agreement had been reached for Abbott Laboratories (NYSE: ABT) (“Abbott”) to acquire Tendyne from Jean Boulle Medtech Ltd and other Tendyne shareholders for a total consideration of US$400million excluding Abbott’s existing 10% of the company.

CE Mark approval received for Tendyne in February 2020 again highlighted the Company’s ability to invent or discover breakthrough technologies, accelerate their development, and achieve a successful exit once their potential is proven. 


Jean Boulle Medtech founded VDYNE, a medical device company focused on the development of a transcatheter replacement valve to treat patients suffering from tricuspid regurgitation (“TR”). VDYNE is currently undertaking late stage pre-clinical testing and will carry out the first-in-man implant of the VDYNE valve in the first quarter of 2021.